Home-based immunoglobulin therapy reduces incidence of neonatal RSV infection.
Respiratory syncytial virus (RSV) infections are responsible for more than 90,000 hospitalizations and 4500 infant and childhood deaths each year. RSV infection, which peaks between January and March, can cause respiratory problems, such as bronchiolitis and pneumonia, in children younger than 2 years old.